Get started
Author

Ellinor Elinder

Observed names: E. Elinder, ELLINOR ELINDER, Elinder Ellinor
Observed institution: Stockholm South General Hospital
ORCID: 0000-0001-8596-5327
Observed ORCID: 0000-0001-8596-5327
OpenAlex ID: A5021395985
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
2021 · Thomas Hatschek, Theodoros Foukakis, et al. · JAMA Oncology · 62
PDF
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2022 · Alexios Matikas, Hemming Johansson, et al. · Clinical Cancer Research · 46
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
2019 · Jonas C. S. Bergh, Anne Andersson, et al. · Journal of Clinical Oncology · 22
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
2024 · Yajing Zhu, Ioannis Zerdes, et al. · Breast Cancer Research and Treatment · 7
PDF
Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements
2024 · Pia Mouhanna, Anders Ståhlberg, et al. · International Journal of Cancer · 6
PDF
97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
2020 · T. Hatschek, A. Andersson, et al. · Annals of Oncology · 5
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
2026 · Nicole L. Brown, Sacha J. Howell, et al. · Breast Cancer Research and Treatment · 4
PDF
Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015–000658-39)
2023 · DELMY OLIVA, BENGT-ÅKE ANDERSSON, et al. · Anticancer Research · 3
PDF
Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.
2019 · Yvonne Brandberg, Anne Andersson, et al. · Journal of Clinical Oncology · 2
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
2022 · Yajing Zhu, Kang Wang, et al. · Journal of Clinical Oncology · 1
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2025 · Alexios Matikas, Hemming Johansson, et al.
Randomized Multicenter Trial of Acupressure in Patients Undergoing Moderately to Highly Emetogenic Chemotherapy
2025 · Delmy Oliva, Mats Nilsson, et al. · Clinical journal of oncology nursing
Abstract P5-02-16: Thymidine kinase activity as a prognostic biomarker for first line CDK4/6 inhibitor efficacy in the Personalised Disease Monitoring in Metastatic Breast Cancer study
2025 · Sacha Howell, Bergqvist Mattias, et al. · Clinical Cancer Research
Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
2023 · Alexios Matikas, Hemming Johansson, et al.
Works count: 32
Citation count: 158
H-index: 5
I10-index: 3
Year
Topic
Type